Proposal of criteria for clinical diagnosis of mild cognitive impairment, dementia and Alzheimer's disease;Propuesta de criterios para el diagnóstico clínico del deterioro cognitivo ligero, la demencia y la enfermedad de Alzheimer

Neurologia

Volumn 17, Issue 1, 2002, Pages 17-32

  Robles, A ^a   Del Ser, T ^a   Alom, J ^a   Pena Casanova J ^a   Barquero, M S ^a   Bermejo, F ^a   Blesa R , ^a   Carnero, C ^a   Dobato, L ^a   Galdos L ^a   Garcia De la Rocha M L ^a   Lopez Pousa S ^a   Manubens, J M ^a   Martinez Lage J M ^a   Munoz D ^a   Olazara J ^a   Pascual, L F ^a   Garcia de Yebenes J ^a   Gil Nagel, A ^a   Chamorro, A ^a   Diez Tejedor E ^a   Leira, R ^a   Luquin R ^a   Mateos, F ^a   more..

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Alzheimer; Dementia; Diagnostic criteria; Mild cognitive impairment

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; MEMORY;

ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS;

EID: 0036323711     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (151)

1. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
2. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria
3. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
4. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop
5. Consenso sobre el diagnóstico de atrofia multisistémica
6. Diagnosis of new variant Creutzfeldt-Jakob disease
7. Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association
8. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
9. Memory and mental status correlates of modified Braak staging
10. Evolution of neuronal changes in the course of Alzheimer's disease
11. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease
12. Staging of Alzheimer's disease-related neurofibrillary changes
13. A Polish pedigree with Alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: Clinical and molecular characterization
14. Cell-type-specific enhacement of amyloid-beta deposition in a novel presenilin-1 mutation (P117L)
15. Aging and the ocurrence of dementia. Findings from a population-based cohort with a large sample of nonagenarians
16. A novel presenilin 1 mutation (Leu166Arg) associated with early-onset Alzheimer disease
17. A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures
18. Critères cliniques de diagnostic des atrophies multi-systématisées
19. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop
20. Staging of Alzheimer-related cortical destruction
21. Neuropathological staging of Alzheimer related changes
22. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in cerebral cortex of patients with Alzheimer's disease
23. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type
24. Memory function in very early Alzheimer's disease
25. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to establish a registry for Alzheimer's disease
26. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures
27. Cued recall and the nature of the memory disorder in dementia
28. The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: Relationship to episodic and semantic memory impairment
29. Attention and executive deficits in Alzheimer's disease. A critical review
30. Executive dysfunction in Alzheimer's disease
31. La neuropsychologie de la maladie d'Alzheimer
32. Differentiation of vascular dementia from AD on neuropsychological tests
33. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease
34. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease
35. Neuropsychological deficits associated with diffuse Lewy body disease
36. Clinical and neuropathological findings in Lewy body dementias
37. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease
38. Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type
39. Subcortical dementia. Review of an emerging concept
40. Subcortical dementia: The neuropsychological evidence
41. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease
42. MRbased hippocampal volumetry in the diagnosis of Alzheimer's disease
43. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease
44. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography
45. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease
46. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of parital volume averaging
47. SPECT in dementia: Clinical and pathological correlation
48. 99m Tc HMPAO in Alzheimer's disease: A population-based study
49. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease
50. Single photon emission computed tomography in Alzheimer's disease
51. Alzheimer disease: Depiction of increased cerebral myo-inositol with proton MR spectroscopy
52. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
53. Cartografía cerebral en pacientes con demencia tipo Alzheimer
54. Temporoparietal electrophysiological differences characterize patients with Alzheimer's disease: A split-half replication study
55. Quantitative EEG mapping, regional cerebral blood flow, and neuropsychological function in Alzheimer's disease
56. Quantitative EEG in patients with presenile and senile dementia of the Alzheimer type
57. Quantitative electroencephalography in Parkinson's disease, dementia, depression and normal aging
58. Moznosti pouzitia automatickej kvantitativnej analyzy elektroencefalogramu v diagnostike demencii
59. EEG findings in depressive pseudodementia and dementia with secondary depression
60. Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer's disease"
61. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
62. CSF tau and Aβ42: Logical biomarkers for Alzheimer's disease?
63. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective
64. Apolipoprotein E genotyping in Alzheimer's disease
65. Apolipoprotein E ε4 association with dementia in a population-based study: The Framingham study
66. Genes contributing to Alzheimer's disease
67. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies
68. Apolipoprotein E: Risk factor for Alzheimer disease
69. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
70. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease
71. The apolipoprotein ε4 allele in patients with Alzheimer's disease
72. Apolipoprotein E: High-avidity to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
73. The genotype 2/2 of the presenilin-1 polymorphism is decreased in Spanish early-onset Alzheimer's disease
74. 2macroglobulin with Alzheimer's disease in a Finnish elderly population
75. New gene tied to common form of Alzheimer's
76. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
77. Genetic association of an alpha2-macroglobulin (VaI1000lle) polymorphism and Alzheimer's disease
78. Role of the lowdensity lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease
79. Aberrant presenilin-1 expression downregulates LDL receptor-related protein (LRP): Is LRP central to Alzheimer's disease pathogenesis?
80. Is the LDL receptor-related protein involved in Alzheimer's disease?
81. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease
82. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease
83. Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene
84. Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism
85. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
86. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease
87. A mitochondrial DNA clone is associated with increased risk for Alzheimer disease
88. Translating cell biology into therapeutic advances in Alzheimer's disease
89. Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease
90. Apolipoprotein E and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases
91. Association of Apolipoprotein EE4 with vascular dementia
92. Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia
93. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
94. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease
95. Pharmacology and clinical efficacy of cholinesterase inhibitors
96. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blinded, placebocontrolled international study
97. Acetylcholinesterase inhibition in dementia with Lewy bodies: Results of a prospective pilot trial
98. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
99. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study
100. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy
101. Drug treatment in Lewy body dementia
102. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
103. From mechanisms to drugs in Alzheimer's disease
104. β-peptide immunization. A possible new treatment for Alzheimer disease
105. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
106. Antibody clears senile plaques
107. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
108. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease
109. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: Review of relevant literature
110. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study
111. Pharmacologic management of Alzheimer disease (part II): Antioxidants, antihypertensives, and ergoloid derivatives
112. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study
113. Estrogen-replacement therapy and Alzheimer's disease in the Italian longitudinal study on aging
114. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
115. The women's health initiative memory study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia
116. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
117. The role of the Maillard reaction in other pathologies: Alzheimer's disease
118. Neue pharmakologische Aspekte zum neurologischen Profil von Propentofyllin
119. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: Overview of phase I and phase II clinical trials
120. Clinical trials in dementia with propentofylline
121. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM-III-R
122. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients
123. Desferrioxamine and Alzheimer's disease: Video home behavior assessment of clinical course and measures of brain aluminum
124. Pharmacologic management of Alzheimer disease (part III): Nonsteroidal antiinflammatory drugs-emerging protective evidence?
125. Intramuscular desferrioxamine in patients with Alzheimer's disease
126. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota, 1980 through 1984
127. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal
128. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease
129. Clinical trial of indomethacin in Alzheimer's disease
130. The glycine site on the NMDA receptor: Structure-activity relationships and possible therapeutic applications
131. Treatment of Alzheimer's disease with sabeluzole: Functional and structural correlates
132. The search for disease-modifying treatment for Alzheimer's disease
133. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
134. A population-based study of dementia in 85-yearolds
135. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
136. High apolipoprotein E epsilon 4 allele frequency in age-related memory decline
137. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
138. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
139. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease
140. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease
141. 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease
142. Discriminant analysis of brain imaging data identifies subjects with early Alzheimer's disease
143. Preclinical prediction of Alzheimer's disease using SPECT
144. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss
145. Articulo en japonés. Resumen en MEDLINE: Cerebral blood flow of patients with age-associated memory impairment and the early stage of Alzheimer's disease. A study by SPECT using the ARG method
146. Age related cognitive decline: A clinical entity? A longitudinal study of cerebral blood flow and memory performance
147. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (part II): Standardization of the neuropathologic assessment of Alzheimer's disease
148. Consensus recommendations for the postmortem diagnosis of Alzheimer's Disease